超声引导下经皮微波消融治疗代谢相关性脂肪肝相关性肝细胞癌(HCC)与乙型肝炎病毒相关性肝细胞癌:倾向评分匹配研究。

IF 3 3区 医学 Q2 ONCOLOGY
International Journal of Hyperthermia Pub Date : 2024-01-01 Epub Date: 2024-10-27 DOI:10.1080/02656736.2024.2419912
Yannan Qiao, Sitong Chen, Yang Liu, Lu Li, Liting He, Zhiyu Han, Fangyi Liu, Zhigang Cheng, Xiaoling Yu, Jie Yu, Chuan Pang, Ping Liang
{"title":"超声引导下经皮微波消融治疗代谢相关性脂肪肝相关性肝细胞癌(HCC)与乙型肝炎病毒相关性肝细胞癌:倾向评分匹配研究。","authors":"Yannan Qiao, Sitong Chen, Yang Liu, Lu Li, Liting He, Zhiyu Han, Fangyi Liu, Zhigang Cheng, Xiaoling Yu, Jie Yu, Chuan Pang, Ping Liang","doi":"10.1080/02656736.2024.2419912","DOIUrl":null,"url":null,"abstract":"<p><strong>Objectives: </strong>To compare the long-term outcomes of microwave ablation (MWA) for primary hepatocellular carcinoma (HCC) in patients with metabolic-associated fatty liver disease (MAFLD) with those infected by hepatitis virus B (HBV).</p><p><strong>Methods: </strong>The clinical data of HCC patients under the treatment of MWA were analyzed retrospectively between 2010 and 2021 at Chinese PLA General Hospital. Patients were divided into MAFLD-HCC and HBV-HCC group according to the chronic liver disease etiology. The propensity score matching (PSM) was performed to reduce the interference of confounders. The primary outcomes were overall survival (OS), recurrence-free survival (RFS), cancer-specific survival (CSS) and intrahepatic distant recurrence (IDR).</p><p><strong>Results: </strong>A total of 648 patients (age range, 18-91 years) with 1019 lesions were enrolled including 601 with HBV-HCC and 47 with MAFLD-HCC. After a variable ratio of 1:<i>n</i> ≤ 4 PSM, 100 patients were included in the HBV-HCC and 41 in the MAFLD-HCC group. No statistical differences in OS and CSS (<i>p</i> = 0.880 and <i>p</i> = 0.980, respectively) were observed between the two groups in the matched cohort, while MAFLD-HCC exhibited better RFS and lower IDR rates compared to HBV-HCC (<i>p</i> = 0.043 and <i>p</i> = 0.041, respectively). Additionally, MAFLD-HCC generated lower ascending range in the liver function indexes like ΔALT (46.7 vs. 98.5, <i>p</i> < 0.001), ΔTBIL (1.9 vs. 7.5, <i>p</i> = 0.001) and ΔAST (38.1 vs. 148.6, <i>p</i> < 0.001) than HBV-HCC after MWA.</p><p><strong>Conclusions: </strong>MWA is an effective treatment for HCC patients with MAFLD. The recurrence prognosis of MAFLD-HCC was better than HBV-HCC and the degree of liver injury after MWA was lower.</p>","PeriodicalId":14137,"journal":{"name":"International Journal of Hyperthermia","volume":null,"pages":null},"PeriodicalIF":3.0000,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Ultrasound-guided percutaneous microwave ablation for metabolic-associated fatty liver disease-related hepatocellular carcinoma (HCC) versus hepatitis virus B-related HCC: a propensity score matching study.\",\"authors\":\"Yannan Qiao, Sitong Chen, Yang Liu, Lu Li, Liting He, Zhiyu Han, Fangyi Liu, Zhigang Cheng, Xiaoling Yu, Jie Yu, Chuan Pang, Ping Liang\",\"doi\":\"10.1080/02656736.2024.2419912\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Objectives: </strong>To compare the long-term outcomes of microwave ablation (MWA) for primary hepatocellular carcinoma (HCC) in patients with metabolic-associated fatty liver disease (MAFLD) with those infected by hepatitis virus B (HBV).</p><p><strong>Methods: </strong>The clinical data of HCC patients under the treatment of MWA were analyzed retrospectively between 2010 and 2021 at Chinese PLA General Hospital. Patients were divided into MAFLD-HCC and HBV-HCC group according to the chronic liver disease etiology. The propensity score matching (PSM) was performed to reduce the interference of confounders. The primary outcomes were overall survival (OS), recurrence-free survival (RFS), cancer-specific survival (CSS) and intrahepatic distant recurrence (IDR).</p><p><strong>Results: </strong>A total of 648 patients (age range, 18-91 years) with 1019 lesions were enrolled including 601 with HBV-HCC and 47 with MAFLD-HCC. After a variable ratio of 1:<i>n</i> ≤ 4 PSM, 100 patients were included in the HBV-HCC and 41 in the MAFLD-HCC group. No statistical differences in OS and CSS (<i>p</i> = 0.880 and <i>p</i> = 0.980, respectively) were observed between the two groups in the matched cohort, while MAFLD-HCC exhibited better RFS and lower IDR rates compared to HBV-HCC (<i>p</i> = 0.043 and <i>p</i> = 0.041, respectively). Additionally, MAFLD-HCC generated lower ascending range in the liver function indexes like ΔALT (46.7 vs. 98.5, <i>p</i> < 0.001), ΔTBIL (1.9 vs. 7.5, <i>p</i> = 0.001) and ΔAST (38.1 vs. 148.6, <i>p</i> < 0.001) than HBV-HCC after MWA.</p><p><strong>Conclusions: </strong>MWA is an effective treatment for HCC patients with MAFLD. The recurrence prognosis of MAFLD-HCC was better than HBV-HCC and the degree of liver injury after MWA was lower.</p>\",\"PeriodicalId\":14137,\"journal\":{\"name\":\"International Journal of Hyperthermia\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":3.0000,\"publicationDate\":\"2024-01-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"International Journal of Hyperthermia\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1080/02656736.2024.2419912\",\"RegionNum\":3,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2024/10/27 0:00:00\",\"PubModel\":\"Epub\",\"JCR\":\"Q2\",\"JCRName\":\"ONCOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"International Journal of Hyperthermia","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1080/02656736.2024.2419912","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/10/27 0:00:00","PubModel":"Epub","JCR":"Q2","JCRName":"ONCOLOGY","Score":null,"Total":0}
引用次数: 0

摘要

研究目的比较代谢相关性脂肪肝(MAFLD)患者与乙型肝炎病毒(HBV)感染者微波消融(MWA)治疗原发性肝细胞癌(HCC)的长期疗效:方法:回顾性分析中国人民解放军总医院2010年至2021年间接受MWA治疗的HCC患者的临床资料。根据慢性肝病病因将患者分为MAFLD-HCC组和HBV-HCC组。为减少混杂因素的干扰,进行了倾向评分匹配(PSM)。主要结果为总生存期(OS)、无复发生存期(RFS)、癌症特异性生存期(CSS)和肝内远处复发(IDR):共有 648 名患者(年龄在 18-91 岁之间)入组,病灶数量为 1019 个,其中包括 601 名 HBV-HCC 患者和 47 名 MAFLD-HCC 患者。经过 1:n ≤ 4 PSM 的可变比例后,100 名患者被纳入 HBV-HCC 组,41 名患者被纳入 MAFLD-HCC 组。在配对队列中,两组患者的 OS 和 CSS 无统计学差异(分别为 p = 0.880 和 p = 0.980),而与 HBV-HCC 相比,MAFLD-HCC 表现出更好的 RFS 和更低的 IDR 率(分别为 p = 0.043 和 p = 0.041)。此外,MAFLD-HCC 的肝功能指标,如 ΔALT(46.7 对 98.5,p = 0.001)和 ΔAST(38.1 对 148.6,p 结论:MWA 是治疗 HBV-HCC 的有效方法:MWA是治疗患有MAFLD的HCC患者的有效方法。MAFLD-HCC的复发预后优于HBV-HCC,且MWA后的肝损伤程度较低。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
Ultrasound-guided percutaneous microwave ablation for metabolic-associated fatty liver disease-related hepatocellular carcinoma (HCC) versus hepatitis virus B-related HCC: a propensity score matching study.

Objectives: To compare the long-term outcomes of microwave ablation (MWA) for primary hepatocellular carcinoma (HCC) in patients with metabolic-associated fatty liver disease (MAFLD) with those infected by hepatitis virus B (HBV).

Methods: The clinical data of HCC patients under the treatment of MWA were analyzed retrospectively between 2010 and 2021 at Chinese PLA General Hospital. Patients were divided into MAFLD-HCC and HBV-HCC group according to the chronic liver disease etiology. The propensity score matching (PSM) was performed to reduce the interference of confounders. The primary outcomes were overall survival (OS), recurrence-free survival (RFS), cancer-specific survival (CSS) and intrahepatic distant recurrence (IDR).

Results: A total of 648 patients (age range, 18-91 years) with 1019 lesions were enrolled including 601 with HBV-HCC and 47 with MAFLD-HCC. After a variable ratio of 1:n ≤ 4 PSM, 100 patients were included in the HBV-HCC and 41 in the MAFLD-HCC group. No statistical differences in OS and CSS (p = 0.880 and p = 0.980, respectively) were observed between the two groups in the matched cohort, while MAFLD-HCC exhibited better RFS and lower IDR rates compared to HBV-HCC (p = 0.043 and p = 0.041, respectively). Additionally, MAFLD-HCC generated lower ascending range in the liver function indexes like ΔALT (46.7 vs. 98.5, p < 0.001), ΔTBIL (1.9 vs. 7.5, p = 0.001) and ΔAST (38.1 vs. 148.6, p < 0.001) than HBV-HCC after MWA.

Conclusions: MWA is an effective treatment for HCC patients with MAFLD. The recurrence prognosis of MAFLD-HCC was better than HBV-HCC and the degree of liver injury after MWA was lower.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
CiteScore
5.90
自引率
12.90%
发文量
153
审稿时长
6-12 weeks
期刊介绍: The International Journal of Hyperthermia
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信